Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus TP in metastatic esophageal squamous cell carcinoma
NCT02611700Phase 3Unknown
- Start
- Nov 2015
- Primary completion
- Dec 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC). Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02611700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611700.